Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180

This study has been completed.
Information provided by:
Novartis Identifier:
First received: May 22, 2009
Last updated: November 19, 2009
Last verified: November 2009
The design of this study will enable an extensive evaluation of safety, tolerability, and PK-PD relationship following 4 weeks of dosing in patients with Coronary heart Disease

Condition Intervention Phase
Coronary Heart Disease
Drug: APL180
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study in Patients With Coronary Heart Disease (CHD) to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of APL180

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Safety and tolerability of APL180 [ Time Frame: Throughout the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics of APL180 [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
  • Evaluate effects of APL180 biomarkers [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
  • Pharmacokinetic-pharmacodynamic relationship of APL180 [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]
  • Effect of APL180 on exploratory biomarkers, [ Time Frame: Throughout the study ] [ Designated as safety issue: No ]

Enrollment: 104
Study Start Date: June 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: APL180 (first dose level) Drug: APL180
Experimental: APL180 (second dose level) Drug: APL180
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female CHD or CHD equivalent patients
  • Body mass index (BMI) must be within the range of 20 to 35 kg/m2,
  • Patient must have been on a stable statin therapy for >8 weeks prior to first dose except for the statin intolerant patients.

Exclusion criteria:

  • Pregnancy
  • Significant illness within two weeks prior to dosing.
  • Triglycerides ≥ 500 mg/dl (5.65 mmol/l)
  • Uncontrolled hypertension
  • Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety.
  • Presence of NYHA Class III or IV chronic heart failure
  • MI or angioplasty (including stenting), acute coronary syndrome (ACS), unstable angina or arterial embolic disease within 6 months prior to do Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00907998

United States, Alabama
Pinnacle Research Group
Anniston, Alabama, United States, AL36207
United States, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
United States, Texas
Icon Clinical Research
San Antonio, Texas, United States, 78230
Novartis Investigator Site
Copenhagen, Denmark
Novartis Investigator Site
Mainz, Germany
Novartis Investigator Site
Mannheim, Germany
Novartis Investigator Site
Neuss, Germany
Novartis Investigator Site
Rehovot, Israel
Novartis Investigator Site
Tel Aviv, Israel
Novartis Investigator Site
Zrifin, Israel
Novartis Investigator Site
Amsterdam, Netherlands
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00907998     History of Changes
Other Study ID Numbers: CAPL180A2210B  EudraCT 2009-010877-19 
Study First Received: May 22, 2009
Last Updated: November 19, 2009
Health Authority: United States: Food and Drug Administration
Israel: Ministry of Health
Netherlands: Medical Ethics Review Committee (METC)
Germany: Ministry of Health
Denmark: Danish Medicines Agency

Keywords provided by Novartis:
Coronary heart disease

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases processed this record on January 17, 2017